Novan to Present at the Virtual Investor 2023 Companies to Watch Event

Rhea-AI Summary

Novan, Inc. (Nasdaq: NOVN) announced that its CEO, Paula Brown Stafford, will present at the Virtual Investor 2023 Companies to Watch Event on January 19, 2023, at 12:00 PM ET. A live video webcast of this presentation will be available on Novan’s website, with a replay accessible for 90 days post-event. Novan is focused on innovative therapies for skin diseases, including berdazimer gel for viral skin infections, and has a robust commercial infrastructure following the acquisition of EPI Health. The company continues to leverage its proprietary nitric oxide-based technology platform, NITRICIL™, for developing new treatments.

Live video webcast on Thursday, January 19th at 12:00 PM ET

DURHAM, N.C., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 19, 2023 at 12:00 PM ET.

A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (novan.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Novan

Novan, Inc. is a medical dermatology company primarily focused on researching, developing, and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs. We are developing berdazimer gel, 10.3% (SB206) as a topical prescription gel for the treatment of viral skin infections, with current emphasis on molluscum contagiosum.

Novan completed the acquisition of EPI Health in early 2022. EPI Health equips the company with a robust commercial infrastructure across sales, marketing, and communications, as well as fully dedicated market access and pharmacy relation teams, promoting products for plaque psoriasis, rosacea, acne and dermatoses. Novan also has a pipeline of potential product candidates using our proprietary nitric oxide-based technology platform, NITRICIL™, to generate new treatments for multiple indications.

INVESTOR AND MEDIA CONTACT:
Jenene Thomas
JTC Team, LLC
833-475-8247
NOVN@jtcir.com

FAQ

When is Novan's live presentation scheduled?

Novan's live presentation is scheduled for January 19, 2023, at 12:00 PM ET.

Where can I watch Novan's investor presentation?

You can watch Novan's investor presentation on the Events page of their website.

What products is Novan focusing on?

Novan is focusing on developing therapies for skin diseases, including berdazimer gel for viral infections.

What is the significance of EPI Health's acquisition for Novan?

The acquisition of EPI Health provides Novan with a strong commercial infrastructure for marketing and sales.

What technology platform does Novan use for its product development?

Novan uses the NITRICIL™ technology platform for developing new treatments across various indications.